Intravitreal aflibercept (Eylea®): A review of its use in patients with macular oedema secondary to central retinal vein occlusion

Drugs and Aging

Volumn 31, Issue 5, 2014, Pages 395-404

  Yang, Lily P H ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

CENTRAL RETINA VEIN OCCLUSION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG TOLERABILITY; EYE DISEASE; FAINTNESS; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; COMPLICATION; MACULAR EDEMA; PATHOPHYSIOLOGY; RETINA VEIN OCCLUSION; TREATMENT OUTCOME;

HUMANS; MACULAR EDEMA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME;

EID: 84900531920     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0176-2     Document Type: Review

References (27)

1. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
2. Figueroa MS, Contreras I. Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion. Drugs. 2012;72(16):2063-71.
3. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9.
4. Evoy KE, Abel SR. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion. Ann Pharmacother. 2013;47(6):819-27.
5. Regeneron Pharmaceuticals Inc. Eylea® (aflibercept) injection: US prescribing information. 2014. http://www.regeneron.com/Eylea/eylea-fpi.pdf. Accessed 31 Mar 2014.
6. European Medicines Agency. Eylea (aflibercept) solution for intravitreal injection: summary of product characteristics. 4 Sep 2013. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002392/ WC500135815.pdf. Accessed 31 Mar 2014.
7. Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012;29(10):839-46.
8. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393-8.
9. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85.
10. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667-8.
11. Ammar DA, Mandava N, Kahook MY. The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina. 2013;33(5):1056-61.
12. Schnichels S, Hagemann U, Januschowski K, et al. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013;97(7):917-23.
13. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal vascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-8.
14. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118(6):1089-97.
15. Christoforidis JB, Williams MM, Kothandaraman S, et al. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37(12):1171-4.
16. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278-84.
17. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202-8.
18. Ogura Y, Korobelnik JF, Roider J, et al. Eighteen-month results of the GALILEO study evaluating intravitreal aflibercept injection (IAI) for macular edema secondary to central retinal vein occlusion (CRVO) [abstract no. 4516]. 2013 Annual Meeting of the Association for Research and Vision in Ophthalmology; 5-9 May 2013; Seattle, WA.
19. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-32.
20. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429-37.
21. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014 Mar. doi:10.1016/j.ophtha.2014.01.027.
22. Stewart MW. Aflibercept (VEGF trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96(9):1157-8.
23. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica. 2012;227(Suppl 1):2-10.
24. Genetech Inc. Lucentis® (ranibizumab injection): US prescribing information. Feb 2014. http://www.gene.com/download/pdf/lucentis-prescribing. pdf. Accessed 31 Mar 2014.
25. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-48.
26. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophtholmology. 2012;119:802-9.
27. US National Institutes of Health. ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 6 Jan 2014.